Company intelligence / Profile preview

Digi.Bio

Amsterdam, North Holland, Netherlandsdigi.bio ↗

Ownership: Private
Development stage: Preclinical

Overview

Digi.Bio has developed an AI-driven lab-on-a-chip platform that enables high-throughput single-cell analysis of therapeutic performance—including cytotoxicity testing and phenotypic profiling—delivering results in under 24 hours with minimal material waste. The technology accelerates the development of life-saving therapies by providing deep insights into cellular heterogeneity and drug efficacy at the single-cell level. No clinical trial results are applicable as it does not develop drugs directly.

Therapeutic areas: Other
Modalities: Cell therapy (including engineered T cell therapies such as CAR-T)AntibodySmall moleculeBiologic (platform agnostic; supports multiple modalities)
Industry: Drug Discovery Services

Beyond the preview

Go deeper on Digi.Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Digi.Bio.

Explore the full profile